Drugs / BR1018-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05460364 | Aug → Oct 2022 | hyperlipidemia, hypertensive disorder | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR1018-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05460364 ↗ |